-
1
-
-
0000286732
-
A minute chromosome in human chronic granulocytic leukemia
-
Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132: 1497.
-
(1960)
Science
, vol.132
, pp. 1497
-
-
Nowell, P.C.1
Hungerford, D.A.2
-
2
-
-
0015694748
-
A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
-
Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
-
(1973)
Nature
, vol.243
, pp. 290-293
-
-
Rowley, J.D.1
-
3
-
-
0020972981
-
Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
-
Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280. (Pubitemid 14232360)
-
(1983)
Nature
, vol.306
, Issue.5940
, pp. 277-280
-
-
Bartram, C.R.1
De Klein, A.2
Hagemeijer, A.3
-
4
-
-
0021346853
-
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
-
Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99. (Pubitemid 14155374)
-
(1984)
Cell
, vol.36
, Issue.1
, pp. 93-99
-
-
Groffen, J.1
Stephenson, J.R.2
Heisterkamp, N.3
-
5
-
-
0025348013
-
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
-
Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
-
(1990)
Science
, vol.247
, pp. 1079-1082
-
-
Lugo, T.G.1
Pendergast, A.M.2
Muller, A.J.3
-
6
-
-
0032834443
-
Analysis of philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization
-
DOI 10.1023/A:1008349405763
-
Seong D, Kantarjian HM, Albitar M, et al. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol. 1999;10:955-959. (Pubitemid 29424576)
-
(1999)
Annals of Oncology
, vol.10
, Issue.8
, pp. 955-959
-
-
Seong, D.1
Kantarjian, H.M.2
Albitar, M.3
Arlinghaus, R.4
Xu, J.5
Talpaz, M.6
Rios, M.B.7
Qiang, G.J.8
O'Brien, S.9
Siciliano, M.10
-
7
-
-
33947224197
-
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
-
Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006; 145:913-923. (Pubitemid 351639967)
-
(2006)
Annals of Internal Medicine
, vol.145
, Issue.12
, pp. 913-923
-
-
Kantarjian, H.M.1
Talpaz, M.2
Giles, F.3
O'Brien, S.4
Cortes, J.5
-
8
-
-
84855482586
-
-
National Institutes of Health. Surveillance Epidemiology and End Results web site. Accessed September 3, 2010
-
National Cancer Institute, National Institutes of Health. Surveillance Epidemiology and End Results web site. Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia. http://seer.cancer.gov/statfacts/html/ cmyl.html. Accessed September 3, 2010.
-
Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia
-
-
-
9
-
-
33644525274
-
Gene expression changes associated with progression and response in chronic myeloid leukemia
-
Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103:2794-2799.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 2794-2799
-
-
Radich, J.P.1
Dai, H.2
Mao, M.3
-
10
-
-
0033614446
-
Chronic myeloid leukemia
-
DOI 10.1056/NEJM199904293401706
-
Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340. (Pubitemid 29196596)
-
(1999)
New England Journal of Medicine
, vol.340
, Issue.17
, pp. 1330-1340
-
-
Sawyers, C.L.1
-
12
-
-
73349122639
-
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
-
Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J ClinOncol. 2009;27:6041-6051.
-
(2009)
J ClinOncol
, vol.27
, pp. 6041-6051
-
-
Baccarani, M.1
Cortes, J.2
Pane, F.3
-
13
-
-
33747154547
-
Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
DOI 10.1182/blood-2006-02-005686
-
Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820. (Pubitemid 44394987)
-
(2006)
Blood
, vol.108
, Issue.6
, pp. 1809-1820
-
-
Baccarani, M.1
Saglio, G.2
Goldman, J.3
Hochhaus, A.4
Simonsson, B.5
Appelbaum, F.6
Apperley, J.7
Cervantes, F.8
Cortes, J.9
Deininger, M.10
Gratwohl, A.11
Guilhot, F.12
Horowitz, M.13
Hughes, T.14
Kantarjian, H.15
Larson, R.16
Niederwieser, D.17
Silver, R.18
Hehlmann, R.19
-
14
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
DOI 10.1056/NEJMoa022457
-
O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.11
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
Cornelissen, J.J.7
Fischer, T.8
Hochhaus, A.9
Hughes, T.10
Lechner, K.11
Nielsen, J.L.12
Rousselot, P.13
Reiffers, J.14
Saglio, G.15
Shepherd, J.16
Simonsson, B.17
Gratwohl, A.18
Goldman, J.M.19
Kantarjian, H.20
Taylor, K.21
Verhoef, G.22
Bolton, A.E.23
Capdeville, R.24
Druker, B.J.25
more..
-
15
-
-
77949767505
-
International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 1126
-
Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1126.
-
(2009)
Blood
, vol.114
-
-
Deininger, M.1
O'Brien, S.G.2
Guilhot, F.3
-
16
-
-
71849108124
-
Imatinib resistance and/or intolerance in clinical practice in Europe. The "Unmet Needs in CML and Ph+ ALL" (UNIC) study
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 1951
-
Michallet M, Morra E, Steegman J, et al. Imatinib resistance and/or intolerance in clinical practice in Europe. The "Unmet Needs in CML and Ph+ ALL" (UNIC) study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110, Abstract 1951.
-
(2007)
Blood
, vol.110
-
-
Michallet, M.1
Morra, E.2
Steegman, J.3
-
17
-
-
84855494380
-
Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice
-
[abstract]. Abstract 6595
-
Davis C, Sanders L, Hirji I, et al. Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 6595.
-
(2008)
J Clin Oncol
, vol.26
, Issue.MAY 20 SUPPL.
-
-
Davis, C.1
Sanders, L.2
Hirji, I.3
-
18
-
-
49149111543
-
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
-
de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-3363.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3358-3363
-
-
De Lavallade, H.1
Apperley, J.F.2
Khorashad, J.S.3
-
19
-
-
54049130762
-
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
-
Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22:1963-1966.
-
(2008)
Leukemia
, vol.22
, pp. 1963-1966
-
-
Lucas, C.M.1
Wang, L.2
Austin, G.M.3
-
20
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
DOI 10.1056/NEJMoa062867
-
Druker BJ, Guilhot F, O'Brien SG, et al. Five-year followup of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.N.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
Hochhaus, A.12
Powell, B.L.13
Gabrilove, J.L.14
Rousselot, P.15
Reiffers, J.16
Cornelissen, J.J.17
Hughes, T.18
Agis, H.19
Fischer, T.20
Verhoef, G.21
Shepherd, J.22
Saglio, G.23
Gratwohl, A.24
Nielsen, J.L.25
Radich, J.P.26
Simonsson, B.27
Taylor, K.28
Baccarani, M.29
So, C.30
Letvak, L.31
Larson, R.A.32
more..
-
21
-
-
33748133844
-
Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials
-
DOI 10.1182/blood-2006-02-001495
-
Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between 2 phase 3 trials. Blood. 2006;108:1478-1484. (Pubitemid 44316111)
-
(2006)
Blood
, vol.108
, Issue.5
, pp. 1478-1484
-
-
Roy, L.1
Guilhot, J.2
Krahnke, T.3
Guerci-Bresler, A.4
Druker, B.J.5
Larson, R.A.6
O'Brien, S.7
So, C.8
Massimini, G.9
Guilhot, F.10
-
22
-
-
67349233062
-
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
-
Hochhaus A, O'Brien S, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-1061.
-
(2009)
Leukemia
, vol.23
, pp. 1054-1061
-
-
Hochhaus, A.1
O'Brien, S.2
Guilhot, F.3
-
23
-
-
58149396984
-
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
-
Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437-4444.
-
(2008)
Blood
, vol.112
, pp. 4437-4444
-
-
Marin, D.1
Milojkovic, D.2
Olavarria, E.3
-
24
-
-
38949178846
-
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
-
DOI 10.1182/blood-2007-07-103523
-
Hochhaus A, Druker B, Sawyers C, et al. Favorable longterm follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. (Pubitemid 351213381)
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1039-1043
-
-
Hochhaus, A.1
Druker, B.2
Sawyers, C.3
Guilhot, F.4
Schiffer, C.A.5
Cortes, J.6
Niederwieser, D.W.7
Gambacorti, C.8
Stone, R.M.9
Goldman, J.10
Fischer, T.11
O'Brien, S.G.12
Reiffers, J.J.13
Mone, M.14
Krahnke, T.15
Talpaz, M.16
Kantarjian, H.M.17
-
25
-
-
10744229080
-
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
-
DOI 10.1056/NEJMoa030513
-
Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.15
, pp. 1423-1432
-
-
Hughes, T.P.1
Kaeda, J.2
Branford, S.3
Rudzki, Z.4
Hochhaus, A.5
Hensley, M.L.6
Gathmann, I.7
Bolton, A.E.8
Van Hoomissen, I.C.9
Goldman, J.M.10
Radich, J.P.11
-
26
-
-
35948937212
-
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
-
DOI 10.1158/1078-0432.CCR-07-1112
-
Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007; 13:6136-6143. (Pubitemid 350075073)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.20
, pp. 6136-6143
-
-
Press, R.D.1
Galderisi, C.2
Yang, R.3
Rempfer, C.4
Willis, S.G.5
Mauro, M.J.6
Druker, B.J.7
Deininger, M.W.N.8
-
27
-
-
57049180944
-
Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: A 6-year follow-up
-
Qin YZ, Jiang B, Jiang Q, et al. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol. 2009;88:37-41.
-
(2009)
Ann Hematol
, vol.88
, pp. 37-41
-
-
Qin, Y.Z.1
Jiang, B.2
Jiang, Q.3
-
28
-
-
39049161669
-
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: Need for new response definitions?
-
DOI 10.1002/cncr.23238
-
Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Need for new response definitions? Cancer. 2008;112:837-845. (Pubitemid 351240578)
-
(2008)
Cancer
, vol.112
, Issue.4
, pp. 837-845
-
-
Kantarjian, H.1
O'Brien, S.2
Shan, J.3
Huang, X.4
Garcia-Manero, G.5
Faderl, S.6
Ravandi-Kashani, F.7
Verstovsek, S.8
Rios, M.B.9
Cortes, J.10
-
29
-
-
77958595179
-
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)
-
Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758-3765.
-
(2010)
Blood
, vol.116
, pp. 3758-3765
-
-
Hughes, T.P.1
Hochhaus, A.2
Branford, S.3
-
30
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-2259.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.-W.2
Issaragrisil, S.3
-
31
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
-
32
-
-
79952787880
-
A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): The S0325 Intergroup Trial
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract LBA-6
-
Radich JP, Kopecky KJ, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract LBA-6.
-
(2010)
Blood
, vol.116
-
-
Radich, J.P.1
Kopecky, K.J.2
Kamel-Reid, S.3
-
33
-
-
77957026184
-
Practical considerations for monitoring patients with chronic myeloid leukemia
-
Branford S, Hughes TP. Practical considerations for monitoring patients with chronic myeloid leukemia. Semin Hematol. 2010;47:327-334.
-
(2010)
Semin Hematol
, vol.47
, pp. 327-334
-
-
Branford, S.1
Hughes, T.P.2
-
34
-
-
37249016890
-
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
-
DOI 10.1158/1078-0432.CCR-07-0844
-
Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13:7080-7085. (Pubitemid 350276891)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.23
, pp. 7080-7085
-
-
Branford, S.1
Seymour, J.F.2
Grigg, A.3
Arthur, C.4
Rudzki, Z.5
Lynch, K.6
Hughes, T.7
-
35
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
-
Mahon FX, Rea D, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
Rea, D.2
Guilhot, F.3
-
36
-
-
33750615550
-
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
-
Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006;108:2811-2813.
-
(2006)
Blood
, vol.108
, pp. 2811-2813
-
-
Kovitz, C.1
Kantarjian, H.2
Garcia-Manero, G.3
Abruzzo, L.V.4
Cortes, J.5
-
37
-
-
34648833625
-
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
-
DOI 10.1002/cncr.22936
-
Deininger MWN, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer. 2007;110:1509-1519. (Pubitemid 47463065)
-
(2007)
Cancer
, vol.110
, Issue.7
, pp. 1509-1519
-
-
Deininger, M.W.N.1
Cortes, J.2
Paquette, R.3
Park, B.4
Hochhaus, A.5
Baccarani, M.6
Stone, R.7
Fischer, T.8
Kantarjian, H.9
Niederwieser, D.10
Gambacorti-Passerini, C.11
So, C.12
Gathmann, I.13
Goldman, J.M.14
Smith, D.15
Druker, B.J.16
Guilhot, F.17
-
38
-
-
35548971639
-
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
-
DOI 10.1182/blood-2007-01-070045
-
Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007;110:2991-2995. (Pubitemid 350006953)
-
(2007)
Blood
, vol.110
, Issue.8
, pp. 2991-2995
-
-
Jabbour, E.1
Kantarjian, H.M.2
Abruzzo, L.V.3
O'Brien, S.4
Garcia-Manero, G.5
Verstovsek, S.6
Shan, J.7
Rios, M.B.8
Cortes, J.9
-
39
-
-
65649147887
-
Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
-
[abstract]. Abstract 7017
-
Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 7017.
-
(2008)
J Clin Oncol
, vol.26
, Issue.MAY 20 SUPPL.
-
-
Giles, F.J.1
Larson, R.A.2
Kantarjian, H.M.3
-
40
-
-
76549116248
-
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
-
Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95:232-240.
-
(2010)
Haematologica
, vol.95
, pp. 232-240
-
-
Shah, N.P.1
Kim, D.W.2
Kantarjian, H.3
-
41
-
-
57349124075
-
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up
-
Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792-1796.
-
(2008)
Haematologica
, vol.93
, pp. 1792-1796
-
-
Palandri, F.1
Castagnetti, F.2
Testoni, N.3
-
42
-
-
59549084574
-
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up
-
Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009;94:205-212.
-
(2009)
Haematologica
, vol.94
, pp. 205-212
-
-
Palandri, F.1
Castagnetti, F.2
Alimena, G.3
-
43
-
-
60049086655
-
Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START Program
-
[abstract]. Abstract 0880
-
Saglio G, Dombret H, Rea D, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START Program [abstract]. Haematologica. 2008;93(S1)349. Abstract 0880.
-
(2008)
Haematologica
, vol.93
, Issue.S1
, pp. 349
-
-
Saglio, G.1
Dombret, H.2
Rea, D.3
-
44
-
-
67650607999
-
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median followup
-
Kantarjian H, Cortes J, Kim D-W, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median followup. Blood. 2009;113:6322-6329.
-
(2009)
Blood
, vol.113
, pp. 6322-6329
-
-
Kantarjian, H.1
Cortes, J.2
Kim, D.-W.3
-
45
-
-
72149111552
-
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
-
[abstract]. Abstract 7057
-
Le Coutre PD, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol. 2009;27(15S). Abstract 7057.
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 S
-
-
Le Coutre, P.D.1
Giles, F.2
Hochhaus, A.3
-
46
-
-
75749090051
-
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
-
Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392-397.
-
(2010)
J Clin Oncol
, vol.28
, pp. 392-397
-
-
Cortes, J.E.1
Jones, D.2
O'Brien, S.3
-
47
-
-
75749129911
-
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
-
Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28:398-404.
-
(2010)
J Clin Oncol
, vol.28
, pp. 398-404
-
-
Cortes, J.E.1
Jones, D.2
O'Brien, S.3
-
48
-
-
77954799488
-
Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 1129
-
Kantarjian HM, Giles FJ, Bhalla KN, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;113. Abstract 1129.
-
(2009)
Blood
, vol.113
-
-
Kantarjian, H.M.1
Giles, F.J.2
Bhalla, K.N.3
-
50
-
-
10744232328
-
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
-
DOI 10.1182/blood-2002-09-2896
-
Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283. (Pubitemid 36759665)
-
(2003)
Blood
, vol.102
, Issue.1
, pp. 276-283
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
Parkinson, I.4
Grigg, A.5
Szer, J.6
Taylor, K.7
Herrmann, R.8
Seymour, J.F.9
Arthur, C.10
Joske, D.11
Lynch, K.12
Hughes, T.13
-
51
-
-
33750077276
-
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
-
DOI 10.1038/sj.leu.2404318, PII 2404318
-
Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773. (Pubitemid 44574988)
-
(2006)
Leukemia
, vol.20
, Issue.10
, pp. 1767-1773
-
-
Jabbour, E.1
Kantarjian, H.2
Jones, D.3
Talpaz, M.4
Bekele, N.5
O'Brien, S.6
Zhou, X.7
Luthra, R.8
Garcia-Manero, G.9
Giles, F.10
Rios, M.B.11
Verstovsek, S.12
Cortes, J.13
-
52
-
-
15944404601
-
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
-
DOI 10.1182/blood-2004-08-3097
-
Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653. (Pubitemid 40446252)
-
(2005)
Blood
, vol.105
, Issue.7
, pp. 2640-2653
-
-
Deininger, M.1
Buchdunger, E.2
Druker, B.J.3
-
53
-
-
61849163272
-
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
-
Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113: 1619-1630.
-
(2009)
Blood
, vol.113
, pp. 1619-1630
-
-
Quintas-Cardama, A.1
Cortes, J.2
-
54
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
DOI 10.1158/0008-5472.CAN-05-0259
-
O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505. (Pubitemid 40740783)
-
(2005)
Cancer Research
, vol.65
, Issue.11
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
Jia, T.4
Manley, P.W.5
Mestan, J.6
Cowan-Jacob, S.W.7
Lee, F.Y.8
Heinrich, M.C.9
Deininger, M.W.N.10
Druker, B.J.11
-
55
-
-
23044458596
-
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
-
DOI 10.1200/JCO.2005.05.531
-
Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005; 23:4100-4109. (Pubitemid 46211315)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4100-4109
-
-
Soverini, S.1
Martinelli, G.2
Rosti, G.3
Bassi, S.4
Amabile, M.5
Poerio, A.6
Giannini, B.7
Trabacchi, E.8
Castagnetti, F.9
Testoni, N.10
Luatti, S.11
De Vivo, A.12
Cilloni, D.13
Izzo, B.14
Fava, M.15
Abruzzese, E.16
Alberti, D.17
Pane, F.18
Saglio, G.19
Baccarani, M.20
more..
-
56
-
-
54349089682
-
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of progression
-
Khorashad JS, de Lavallade H, Apperley J, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of progression. J Clin Oncol. 2008;26:4806-4813.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4806-4813
-
-
Khorashad, J.S.1
De Lavallade, H.2
Apperley, J.3
-
57
-
-
35448967331
-
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
-
DOI 10.1016/S1470-2045(07)70342-X, PII S147020450770342X
-
Apperley JF. Part 1: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8: 1018-1029. (Pubitemid 47629897)
-
(2007)
Lancet Oncology
, vol.8
, Issue.11
, pp. 1018-1029
-
-
Apperley, J.F.1
-
58
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
DOI 10.1126/science.1062538
-
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880. (Pubitemid 32743979)
-
(2001)
Science
, vol.293
, Issue.5531
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Nagesh, R.P.6
Sawyers, C.L.7
-
59
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
DOI 10.1038/sj.leu.2402741
-
Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196. (Pubitemid 35331833)
-
(2002)
Leukemia
, vol.16
, Issue.11
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
La, R.P.4
Muller, M.C.5
Lahaye, T.6
Hanfstein, B.7
Schoch, C.8
Cross, N.C.P.9
Berger, U.10
Gschaidmeier, H.11
Druker, B.J.12
Hehlmann, R.13
-
60
-
-
9444282642
-
Active transport of imatinib into and out of cells: Implications for drug resistance
-
DOI 10.1182/blood-2003-12-4276
-
Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739-3745. (Pubitemid 39564452)
-
(2004)
Blood
, vol.104
, Issue.12
, pp. 3739-3745
-
-
Thomas, J.1
Wang, L.2
Clark, R.E.3
Pirmohamed, M.4
-
61
-
-
26944452899
-
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia
-
DOI 10.1038/sj.leu.2403853, PII 2403853
-
Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia. 2005;19:1590-1596. (Pubitemid 43090403)
-
(2005)
Leukemia
, vol.19
, Issue.9
, pp. 1590-1596
-
-
Zong, Y.1
Zhou, S.2
Sorrentino, B.P.3
-
62
-
-
37049028176
-
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity
-
DOI 10.1182/blood-2007-06-093617
-
White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007; 110:4064-4072. (Pubitemid 350248463)
-
(2007)
Blood
, vol.110
, Issue.12
, pp. 4064-4072
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
Engler, J.4
Venables, A.5
Zrim, S.6
Zannettino, A.7
Lynch, K.8
Manley, P.W.9
Hughes, T.10
-
63
-
-
79956130861
-
Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
-
[abstract]. Abstract 6512
-
Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily [abstract]. J Clin Oncol. 2010;28(15S). Abstract 6512.
-
(2010)
J Clin Oncol
, vol.28
, Issue.15 S
-
-
Shah, N.P.1
Cortes, J.E.2
Schiffer, C.A.3
-
64
-
-
79952014676
-
Resistance, outcome and the development of mutations with dasatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP)
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 1122
-
Shah N, Bahceci E, Lambert A, et al. Resistance, outcome and the development of mutations with dasatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1122.
-
(2009)
Blood
, vol.114
-
-
Shah, N.1
Bahceci, E.2
Lambert, A.3
-
65
-
-
70349306853
-
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: Response dynamics and predictive value
-
Hochhaus A, Muller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 2009;23:1628-1633.
-
(2009)
Leukemia
, vol.23
, pp. 1628-1633
-
-
Hochhaus, A.1
Muller, M.C.2
Radich, J.3
-
66
-
-
76249090055
-
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?
-
Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009; 114:5426-5435.
-
(2009)
Blood
, vol.114
, pp. 5426-5435
-
-
Branford, S.1
Melo, J.V.2
Hughes, T.P.3
-
67
-
-
70349245253
-
Long-term outcome with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
-
Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009;114:2037-2043.
-
(2009)
Blood
, vol.114
, pp. 2037-2043
-
-
Jabbour, E.1
Jones, D.2
Kantarjian, H.M.3
-
68
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
DOI 10.1182/blood-2007-03-080689
-
Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546. (Pubitemid 350159618)
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
Bhalla, K.4
Alimena, G.5
Palandri, F.6
Ossenkoppele, G.J.7
Nicolini, F.-E.8
O'Brien, S.G.9
Litzow, M.10
Bhatia, R.11
Cervantes, F.12
Haque, A.13
Shou, Y.14
Resta, D.J.15
Weitzman, A.16
Hochhaus, A.17
Le, C.P.18
-
69
-
-
79551516839
-
Response and outcomes to nilotinib at 24 months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 1130
-
Radich JP, Martinelli G, Hochhaus A, et al. Response and outcomes to nilotinib at 24 months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1130.
-
(2009)
Blood
, vol.114
-
-
Radich, J.P.1
Martinelli, G.2
Hochhaus, A.3
-
70
-
-
70249105789
-
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
-
Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204-4210.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4204-4210
-
-
Hughes, T.1
Saglio, G.2
Branford, S.3
-
71
-
-
73949105873
-
Dasatinib treatment of chronic phase chronic myeloid leukemia: Analysis of responses according to pre-existing BCR-ABL mutations
-
Muller MC, Cortes JC, Kim D-W, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood. 2009;114:4944-4953.
-
(2009)
Blood
, vol.114
, pp. 4944-4953
-
-
Muller, M.C.1
Cortes, J.C.2
Kim, D.-W.3
-
72
-
-
50949119729
-
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
-
Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112:516-518.
-
(2008)
Blood
, vol.112
, pp. 516-518
-
-
Tam, C.S.1
Kantarjian, H.2
Garcia-Manero, G.3
-
73
-
-
76549114789
-
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
-
Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2010; 95:224-231.
-
(2010)
Haematologica
, vol.95
, pp. 224-231
-
-
Milojkovic, D.1
Nicholson, E.2
Apperley, J.F.3
-
74
-
-
77953208869
-
+ CML chronic phase patients: First results from the randomized CELSG phase III CML 11 "ISTA-HIT" study
-
+ CML chronic phase patients: first results from the randomized CELSG phase III CML 11 "ISTA-HIT" study. Haematologica. 2010;95:908-913.
-
(2010)
Haematologica
, vol.95
, pp. 908-913
-
-
Petzer, A.L.1
Wolf, D.2
Fong, D.3
-
75
-
-
75749105885
-
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study
-
Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28:424-430.
-
(2010)
J Clin Oncol
, vol.28
, pp. 424-430
-
-
Cortes, J.E.1
Baccarani, M.2
Guilhot, F.3
-
76
-
-
34147174980
-
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
-
DOI 10.1182/blood-2006-07-036012
-
Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499. (Pubitemid 46572540)
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3496-3499
-
-
Picard, S.1
Titier, K.2
Etienne, G.3
Teilhet, E.4
Ducint, D.5
Bernard, M.-A.6
Lassalle, R.7
Marit, G.8
Reiffers, J.9
Begaud, B.10
Moore, N.11
Molimard, M.12
Mahon, F.-X.13
-
77
-
-
43249083718
-
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study
-
Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
-
(2008)
Blood
, vol.111
, pp. 4022-4028
-
-
Larson, R.A.1
Druker, B.J.2
Guilhot, F.3
-
78
-
-
57049115901
-
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
-
Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009;33:271-275.
-
(2009)
Leuk Res
, vol.33
, pp. 271-275
-
-
Forrest, D.L.1
Trainor, S.2
Brinkman, R.R.3
-
79
-
-
78650625238
-
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
-
SPIRIT Investigators; France Intergroupe des Leucemies Myelloides Chroniques (Fi-LMC)
-
Preudhomme C, Guilhot J, Nicolini FE, et al. SPIRIT Investigators; France Intergroupe des Leucemies Myelloides Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363:2511-2521.
-
(2010)
N Engl J Med
, vol.363
, pp. 2511-2521
-
-
Preudhomme, C.1
Guilhot, J.2
Nicolini, F.E.3
-
80
-
-
84855507276
-
Superior CMR-rates with tolerability-adapted imatinib 800 mg vs 400 mg vs 400 mg plus IFN in CML: The randomized German CML-Study IV
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 357
-
Hehlmann R, Jung-Munkwitz S, Lauseker M, et al. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs 400 mg vs 400 mg plus IFN in CML: the randomized German CML-Study IV [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 357.
-
(2010)
Blood
, vol.116
-
-
Hehlmann, R.1
Jung-Munkwitz, S.2
Lauseker, M.3
-
81
-
-
79251527895
-
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte- macrophage colony-stimulating factor
-
Cortes J, Quintas-Cardama A, Jones D, et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011;117:572-580.
-
(2011)
Cancer
, vol.117
, pp. 572-580
-
-
Cortes, J.1
Quintas-Cardama, A.2
Jones, D.3
-
82
-
-
43449118108
-
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
-
DOI 10.3324/haematol.12265
-
Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica. 2008;93:770-774. (Pubitemid 351669320)
-
(2008)
Haematologica
, vol.93
, Issue.5
, pp. 770-774
-
-
Palandri, F.1
Iacobucci, I.2
Castagnetti, F.3
Testoni, N.4
Poerio, A.5
Amabile, M.6
Breccia, M.7
Intermesoli, T.8
Iuliano, F.9
Rege-Cambrin, G.10
Tiribelli, M.11
Miglino, M.12
Pane, F.13
Saglio, G.14
Martinelli, G.15
Rosti, G.16
Baccarani, M.17
-
83
-
-
67049087117
-
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study
-
Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401-5411.
-
(2009)
Blood
, vol.113
, pp. 5401-5411
-
-
Noens, L.1
Van Lierde, M.A.2
De Bock, R.3
-
84
-
-
77952467377
-
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
-
Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2381-2388
-
-
Marin, D.1
Bazeos, A.2
Mahon, F.X.3
-
85
-
-
77950402447
-
Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 338
-
Cortes J, Borthakur G, O'Brien S, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 338.
-
(2009)
Blood
, vol.114
-
-
Cortes, J.1
Borthakur, G.2
O'Brien, S.3
-
86
-
-
77950426669
-
Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 341
-
Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114 Abstract 341.
-
(2009)
Blood
, vol.114
-
-
Cortes, J.1
O'Brien, S.2
Jones, D.3
-
87
-
-
79953320397
-
Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): Results of a phase 2 GIMEMA CML Working Party clinical trial
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 359
-
Rosti G, Castagnetti F, Gugliotta G, et al. Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML Working Party clinical trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 359.
-
(2010)
Blood
, vol.116
-
-
Rosti, G.1
Castagnetti, F.2
Gugliotta, G.3
-
88
-
-
79952038063
-
ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 207
-
Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 207.
-
(2010)
Blood
, vol.116
-
-
Hughes, T.P.1
Hochhaus, A.2
Saglio, G.3
-
89
-
-
79952038795
-
Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up
-
[abstract]. (ASH Annual Meeting Abstracts). Abstract 206
-
Shah N, Kantarjian H, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 206.
-
(2010)
Blood
, vol.116
-
-
Shah, N.1
Kantarjian, H.2
Hochhaus, A.3
|